Remove Clinical Development Remove Compound Screening Remove FDA Approval Remove Licensing
article thumbnail

Taking a new approach to tackle neurodegenerative diseases

Drug Discovery World

New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).